The ADC binds a surface antigen (e.g., TROP2), is internalized, and releases brengitecan, which inhibits DNA topoisomerase I to cause DNA damage and kill the antigen-positive cells; topoisomerase I is the intracellular payload target, not the directly targeted cell-surface antigen.